Welcome : Guest

BOTULINUM TOXIN - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Botulinum Toxin in US$ Million by the following Segments: Cosmetic Applications, and Therapeutic Applications. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 14 companies including many key and niche players such as -

Allergan Plc
Daewoong Pharmaceutical Co., Ltd.
HUGEL Pharma
Ipsen Group
Medy-Tox Inc.
Merz Pharma GmbH & Co. KGaA

Click here to request a full list of companies covered in the report...

Code: MCP-1833
Price: $4950
Companies: 14
Pages: 190
Date: January 2018
Market Data Tables: 61
  Status: * New Report



TABLE OF CONTENTS


  BOTULINUM TOXIN (Complete Report) Pages : 190   | $4950

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Botulinum Toxin: Expanding Cosmetic & Therapeutic Applications to Propel Growth.....II-11$100
   Therapeutic BTX Applications Lead, Cosmetic BTX Gradually Gaining Momentum.....II-2 1$100
   Table 1: Global Therapeutic BTX Neurotoxin Market (2016): Percentage Breakdown of Value Sales by Therapeutic Indication (includes corresponding Graph/Chart).....II-3
Developed Regions Dominate Botulinum Toxin Market.....II-3
1$350
   Developing Markets to Drive Future Growth.....II-41$100
   Increase in Healthcare Spending Stirs Demand for BTX in Therapeutic
  Applications.....II-5
1$100
   Table 2: Healthcare Spending as % of GDP by Geographic Region (2016) (includes corresponding Graph/Chart).....II-61$350
   Table 3: Per Capita Healthcare Spending (in $) in Select Developed Countries for the Year 2016 (includes corresponding Graph/Chart).....II-7
Cosmetic BTX – A Promising Application Market.....II-7
1$350
   Factors Propelling the Cosmetic BT Market – In a Nut Shell.....II-81$100
   Rise in the Number of Musculoskeletal Indications – Potential for Growth.....II-91$100
   Pharma Companies Keenly Eye Lucrative BT Market.....II-101$100
   Intense Competition Characterizes Botulinum Toxin Market.....II-11
Allergan Leads the Global BTX Market.....II-11
1$100
   Table 4: Leading Products in the Global Aesthetic Botulinum Toxin Market (2016): Percentage Breakdown of Value Sales for Botox, Dysport, Dysport/Azzalure, Meditoxin, and Xeomin (includes corresponding Graph/Chart).....II-12
Botulinum Toxin Products Worldwide.....II-12
1$350
   Botox – The Leading Brand in Cosmetic BTX Market.....II-13
Biosimilar BTX Variants Challenge Botox’s Leadership.....II-13
1$100
   Lack of Differentiation among Approved BTX Products.....II-14
Comparison of Leading Neurotoxins - Botox, Dysport and Xeomin by Safety and
  Efficacy.....II-14
Daewoong Pharmaceutical All Set to Make a Mark on the International Scenario.....II-14
1$100
   A Review of Major BTX Products.....II-15
Comparison of Botox®, Dysport® and Xeomin® by Indications and Year of
  Approval.....II-15
1$100
   BOTOX®.....II-161$100
   Approvals and Indications of Botox in Select Regions.....II-171$100
   Key Characteristics of Botox® and Botox® Cosmetic.....II-18
Common Adverse Reactions with Botox.....II-18
Therapeutics to Offer Higher Prospects for Botox.....II-18
1$100
   Botox Therapeutic Approvals in the US by Indication.....II-19
Migraine Indication Bolsters Allergan’s Botox Sales.....II-19
1$100
   Dysport®.....II-20
Key Characteristics of Dysport®.....II-20
Ipsen Counts on New Indications for Future Growth of Dysport.....II-20
1$100
   Dysport Therapeutic Development Pipeline by Region.....II-21
Xeomin®.....II-21
Key Characteristics of Xeomin®.....II-21
1$100
   Xeomin® FDA Approval and Indications.....II-22
Global Expansion Helps Merz Gain in the BTX Market.....II-22
Myobloc®/NeuroBloc®.....II-22
1$100
   Key Characteristics of Myobloc®.....II-23
Meditoxin®.....II-23
RT002.....II-23
1$100
   Other Products.....II-241$100
   Rising Demand for Non-Invasive Cosmetic Treatments Bodes Well for BTX Market.....II-25 1$100
   Table 5: Non-Surgical Cosmetic Procedures Worldwide (2016): Percentage Breakdown of Procedure Volume for Injectables (Botulinum Toxin, Calcium Hydroxylapatite, Hyaluronic Acid and Poly-L-Lactic Acid), Facial Rejuvenation and Others (includes corresponding Graph/Chart).....II-26
Botulinum Toxin – The Preferred Solution in Facial Injectables Market.....II-26
1$350
   Table 6: Global Dermal Fillers Market by Application (2017): Percentage Breakdown of Value Sales for Face Lift Treatment, Facial Line Correction Treatment, Lip Treatment and Others (includes corresponding Graph/Chart).....II-27

Table 7: Cosmetic Botulinum Toxin Procedures Performed Worldwide (2016): Percentage Breakdown of Procedure Volume by Gender (includes corresponding Graph/Chart).....II-27
1$350
   Table 8: Number of Cosmetic Botulinum Toxin Procedures (in ‘000s) in Select Countries for the Year 2016 (includes corresponding Graph/Chart).....II-281$350
   Botox Gains Popularity among Millennials.....II-29
Table 9: Cosmetic Botulinum Toxin Procedures Performed Worldwide (2016): Percentage Breakdown of Procedure Volume by Age Group (includes corresponding Graph/Chart).....II-29
Longer Life Expectancy and Rising Disposable Incomes Propel Sales of Cosmetic
  BTX.....II-29
1$350
   Table 10: Life Expectancy at Birth in Years of People in Select Countries (2017) (includes corresponding Graph/Chart).....II-301$350
   Table 11: Life Expectancy at Birth (in Years) of Men and Women by Region (2017) (includes corresponding Graph/Chart).....II-31
BTX – The Wonder Drug for Increasing Number of Non-Cosmetic Uses.....II-31
1$350
   BoNT/X – The New Toxin with Potential Use in New Therapeutic Areas.....II-321$100
   Topical Botulinum Toxin: Needle-Free Administration Imparts an Edge over Injected
  Variants.....II-33
1$100
   Unmet Medical Needs Encourage Off-Label Use: A Cause for Concern or
  Jubilation?.....II-34
Urgent Need for Physician Education about Off-Label Usage.....II-34
1$100
   Campaigns Boost Patient Awareness.....II-35
Digital Revolution to Impact Consumer Choices.....II-35
Financing of Non-Reimbursed Healthcare: Need of the Hour.....II-35
1$100
   Combination Therapies: A Double Whammy Success.....II-36
Botulinum Toxin – Potential Applications in Treatment of Dental Diseases.....II-36
1$100
   Short-lived Aesthetic Effects: A Strong Business Case for Revision Treatments.....II-37
Novel Injection Systems for Highly Precise Dosage of Botulinum Toxin.....II-37
1$100
   Undesirable Side Effects: A Challenge to Reckon With.....II-381$100
   Immunogenicity Undermines Patient Compliance.....II-39
Reduction of Protein Load in BTX Products – The Probable Answer for
  Immunogenicity.....II-39
Antigenicity: A Problematic Issue in Drug Development.....II-39
1$100
   Stringent Regulations Delay Market Approvals & Put Reimbursements in Limbo.....II-40
Study Offers Support for Possible Remote Effects with Botulinum Toxin.....II-40
Higher Product Costs to Challenge Market Growth.....II-40
1$100
   Consumer Skepticism: The Biggest Challenge to Beat.....II-41
Animal Cruelty – A Part & Parcel of Botox Testing.....II-41
Botulinum Toxins – A Wonder Drug or Bio-terror Threat?.....II-41
1$100
   Fears of Terrorism & Biological Warfare Thwart International Trade.....II-421$100
   Botulinum Toxin: A Poison That Cures.....II-43
Structure & Mechanism of Action.....II-43
1$100
   Disadvantages.....II-44
Classification of Botulinum Toxin.....II-44
Botulinum Toxin Type A.....II-44
1$100
   Historical Timeline of Botulinum Toxin: 1885-2002.....II-45
Botulinum Toxin Type B.....II-45
Procedure.....II-45
Anaesthesia.....II-45
1$100
   Injection Procedure.....II-46
Applications of Botulinum Toxin.....II-46
Cosmetic Applications.....II-46
Glabellar Lines.....II-46
Facial Wrinkles.....II-46
1$100
   Key Cosmetic Indications for Botulinum Toxin.....II-47
Crow's Feet.....II-47
Forehead Rhytids.....II-47
Temporal Brow Lift.....II-47
1$100
   Lower Eyelid Rhytids.....II-48
Downturned Lips.....II-48
Pebbly Chin.....II-48
Therapeutic Applications.....II-48
Movement Disorders/Pain.....II-48
Cervical Dystonia.....II-48
1$100
   Hemifacial Spasm.....II-49
Blepharospasm.....II-49
Strabismus.....II-49
1$100
   Site of Injection and Doses of Neurotoxins used in the Treatment of
  Dystonias.....II-50
1$100
   Chronic Pain.....II-51
Botox in Migraine Treatment.....II-51
1$100
   List of Countries where Botox has been Approved for Prophylaxis of Headache
  in Adults Suffering from Chronic Migraine.....II-52
Table 12: Modes of Injection of Onabotulinum ToxinA for Chronic Migraine by Dose and Muscle Injected (includes corresponding Graph/Chart).....II-52
1$350
   Hyperhidrosis.....II-53
Bladder Dysfunctions.....II-53
Spasticity.....II-53
Other Applications.....II-53
1$100
   Side Effects.....II-541$100
   Ipsen Gains FDA Approval for Dysport® in Treatment of Lower Limb Spasticity Treatment
  in Adults.....II-55
Medytox to Introduce Coretox Protein Free Botox Product.....II-55
Allergan’s BOTOX® Cosmetic Wins FDA Approval for Third Indication.....II-55
Ipsen Gains FDA Approval for Dysport® in Treatment of Pediatric Lower Limb
  Spasticity.....II-55
Merz Receives European Approval for Bocouture® Use in Treatment of Upper Facial
  Lines.....II-55
Merz Announces Availability of Xeomin® 200-unit Single-Dose Vial in US.....II-55
1$100
   FDA Approves BOTOX® for Treatment of Adult Lower Limb Spasticity.....II-561$100
   Allergan’s VISTABEL® Receives Positive Opinion for Severe Forehead Lines Treatment in
  Adults.....II-57
Merz and Teijin Partner to Commercialize Xeomin® in Japan.....II-57
Ipsen Inks Promotion Agreement with Saol Therapeutics.....II-57
Bain Capital Takes Over Hugel.....II-57
Huons to Invest in New BTX Plant in Korea.....II-57
Allergan Gains Marketing Approval for BOTOX Vista® in Japan.....II-57
1$100
   Allergan Takes Over Anterios.....II-58
Daewoong Pharm Expands Sales of Nabota BTX Biosimilar to Southeast Asia.....II-58
Revance Acquires BTX-related IP from Botulinum Toxin Research Associates.....II-58
Revance Releases Phase 2 Trial Results of RT001 Topical Botulinum Toxin Type A Drug
  Candidate.....II-58
Ipsen Collaborates with EpiVax for Developed Next-Gen Botulinum Toxins.....II-58
Revance Begins Phase 3 Clinical Trial for Botulinum Toxin Type A Topical Gel.....II-58
1$100
   Revance Commences Phase 2 Study for RT002 Botulinum Toxin Type A.....II-59
Revance Begins Phase 2 Trial for Botulinum toxin Type A Topical Gel.....II-59
Bloomage BioTechnology and Medytox to Establish JV in China.....II-59
Ipsen Gains FDA’s sBLA Approval for Dysport®.....II-59
Actavis Bags FDA Approval for Expanding BOTOX® Label.....II-59
Actavis Acquires Allergan.....II-59
1$100
   Allergan Plc (Ireland).....II-60
Daewoong Pharmaceutical Co., Ltd. (South Korea).....II-60
HUGEL Pharma (South Korea).....II-60
1$100
   Ipsen Group (France).....II-61
Medy-Tox Inc. (South Korea).....II-61
1$100
   Merz Pharma GmbH & Co. KGaA (Germany).....II-62
Metabiologics, Inc. (USA).....II-62
Revance Therapeutics, Inc. (USA).....II-62
1$100
   US WorldMeds (USA).....II-631$100
   Table 13: World Recent Past, Current & Future Analysis for Botulinum Toxin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Thousand for the Years 2016 through 2024 (includes corresponding Graph/Chart).....II-641$350
   Table 14: World Historic Review for Botulinum Toxin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Thousand for the Years 2011 through 2015 (includes corresponding Graph/Chart).....II-651$350
   Table 15: World 14-Year Perspective for Botulinum Toxin by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for the Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....II-661$350
   Table 16: World Recent Past, Current & Future Analysis for Botulinum Toxin in Cosmetic Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Thousand for the Years 2016 through 2024 (includes corresponding Graph/Chart).....II-671$350
   Table 17: World Historic Review for Botulinum Toxin in Cosmetic Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Thousand for the Years 2011 through 2015 (includes corresponding Graph/Chart).....II-681$350
   Table 18: World 14-Year Perspective for Botulinum Toxin in Cosmetic Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for the Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....II-691$350
   Table 19: World Recent Past, Current & Future Analysis for Botulinum Toxin in Therapeutic Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Thousand for the Years 2016 through 2024 (includes corresponding Graph/Chart).....II-701$350
   Table 20: World Historic Review for Botulinum Toxin in Therapeutic Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Thousand for the Years 2011 through 2015 (includes corresponding Graph/Chart).....II-711$350
   Table 21: World 14-Year Perspective for Botulinum Toxin in Therapeutic Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for the Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....II-721$350
   A. Market Analysis.....III-1
Current and Future Analysis.....III-1
Therapeutic BTX Market – New Entrants Slow in Gaining Market Share.....III-1
Approved Therapeutic Indications of Botulinum Toxin in the US by Year of
  Approval.....III-1
1$75
   Neurogenic OAB – A Relatively Smaller Market Opportunity.....III-2
Idiopathic OAB Bodes Healthy Prospects for Botox.....III-2
Cosmetic BTX Market: Rapid Growth in Store.....III-2
2$150
   Table 22: Age-wise Distribution for Botulinum Toxin Procedures Performed in the US for the Year 2016 (includes corresponding Graph/Chart).....III-4

Table 23: Gender Distribution for Botulinum Toxin Procedures Performed in the US (2016) (includes corresponding Graph/Chart).....III-4
Increasing Demand for Cosmetic Treatments Bodes Well for BTX Market.....III-4
1$200
   Some Interesting Facts on Cosmetic Procedures.....III-5 1$75
   Table 24: Number of Surgical & Non-Surgical Cosmetic Procedures ('000s) in the US for the Years 1997, 2015 & 2016 (includes corresponding Graph/Chart).....III-61$200
   Table 25: Top 5 Surgical Cosmetic Procedures in the US - Ranked by the Number of Procedures Performed (In ‘000s) for 2016 (includes corresponding Graph/Chart).....III-7

Table 26: Top 5 Non-Surgical Cosmetic Procedures in the US - Ranked by the Number of Procedures Performed (‘000s) for 2016 (includes corresponding Graph/Chart).....III-7
1$200
   Table 27: Total Number of Cosmetic Procedures Performed by Category in the US (2016) (includes corresponding Graph/Chart).....III-81$200
   Table 28: Number of Botulinum Toxin Procedures Performed in the US (1997, 2015 and 2016) (includes corresponding Graph/Chart).....III-9
Demand for Professional Help On Rise.....III-9
Aging Baby Boomers Drive Aesthetic Business.....III-9
Table 29: US Population by Age Group (2017): Percentage Breakdown for 0-14, 15-24, 25-59 and 65+ Age Groups (includes corresponding Graph/Chart).....III-9
1$200
   Table 30: North American Aging Population by Age Group: 1975-2050 (includes corresponding Graph/Chart).....III-10
Expanding Physician Base Extends Impetus to Growth.....III-10
1$200
   Table 31: Average Physician/Surgeon Fees for Botulinum Toxin Per Procedure in the US (2007- 2016) (includes corresponding Graph/Chart).....III-11
Competitive Landscape.....III-11
Allergan’s Botox Leads Cosmetic BTX Market.....III-11
1$200
   Major BTX Products and Associated Fillers in the Cosmetic Botulinum Toxin
  Market.....III-12
Table 32: Leading Brands in the US Cosmetic Neurotoxin Treatment Market (2016): Percentage Breakdown of Value Sales for Botox, Dysport and Others (includes corresponding Graph/Chart).....III-12
Dysport Takes on Botox in the Therapeutic Space.....III-12
1$200
   Table 33: Leading Brands in the US Therapeutic Botulinum Toxin Market (2016): Percentage Breakdown of Value Sales for Botox and Dysport (includes corresponding Graph/Chart).....III-13
AAN Releases New Guidelines on BTX for Identified Disorders.....III-13
1$200
   Rise in Botulinum Toxin Lawsuits – A Concern for Physicians?.....III-14
Product Launches/Approvals.....III-14
2$150
   Strategic Corporate Developments.....III-161$75
   Key Players.....III-172$150
   B. Market Analytics.....III-19
Table 34: US Recent Past, Current & Future Analysis for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Thousand for the Years 2016 through 2024 (includes corresponding Graph/Chart).....III-19
1$200
   Table 35: US Historic Review for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Thousand for the Years 2011 through 2015 (includes corresponding Graph/Chart).....III-201$200
   Table 36: US 14-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Dollar Sales for Cosmetic and Therapeutic Markets for the Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-211$200
   Market Analysis.....III-22
Table 37: Canadian Recent Past, Current & Future Analysis for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Thousand for the Years 2016 through 2024 (includes corresponding Graph/Chart).....III-22
1$200
   Table 38: Canadian Historic Review for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Thousand for the Years 2011 through 2015 (includes corresponding Graph/Chart).....III-231$200
   Table 39: Canadian 14-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Dollar Sales for Cosmetic and Therapeutic Markets for the Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-241$200
   A. Market Analysis.....III-25
Current and Future Analysis.....III-25
Table 40: Non-Surgical Aesthetic Procedures in Japan (2016): Percentage Breakdown of Number of Procedures by Procedure Type (includes corresponding Graph/Chart).....III-25
Strategic Corporate Developments.....III-25
1$200
   B. Market Analytics.....III-26
Table 41: Japanese Recent Past, Current & Future Analysis for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Thousand for the Years 2016 through 2024 (includes corresponding Graph/Chart).....III-26
1$200
   Table 42: Japanese Historic Review for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Thousand for the Years 2011 through 2015 (includes corresponding Graph/Chart).....III-271$200
   Table 43: Japanese 14-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Dollar Sales for Cosmetic and Therapeutic Markets for the Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-281$200
   A. Market Analysis.....III-29
Current and Future Analysis.....III-29
BTX Cosmetic Market Positioned for Growth.....III-29
Botox Approvals and Indications in Select European Countries.....III-29
1$75
   Table 44: Non-Surgical Aesthetic Procedures in Select European Countries (2016): Percentage Breakdown of Number of Procedures by Procedure Type (includes corresponding Graph/Chart).....III-30
Anti-Aging Treatment on the Rise among Young Mothers.....III-30
1$200
   Regulations for Botulinum Toxin Usage in the EU.....III-31
The United Kingdom.....III-31
Cosmetic Treatment Procedures in the UK.....III-31
1$75
   Snapshots.....III-321$75
   Russia.....III-33
Mandates Registration of BTX Drugs.....III-33
Strategic Corporate Developments.....III-33
1$75
   Key Players.....III-342$150
   B. Market Analytics.....III-36
Table 45: European Recent Past, Current & Future Analysis for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Thousand for the Years 2016 through 2024 (includes corresponding Graph/Chart).....III-36
1$200
   Table 46: European Historic Review for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Thousand for the Years 2011 through 2015 (includes corresponding Graph/Chart).....III-371$200
   Table 47: European 14-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Dollar Sales for Cosmetic and Therapeutic Markets for the Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-381$200
   A. Market Analysis.....III-39
Current and Future Analysis.....III-39
Botox Approvals and Indications in Select Asian Countries.....III-39
A PEEK INTO SELECT MARKETS.....III-39
Australia.....III-39
1$75
   Table 48: Non-Surgical Aesthetic Procedures in Australia (2016): Percentage Breakdown of Number of Procedures by Procedure Type (includes corresponding Graph/Chart).....III-40
China.....III-40
Rising Demand for Cosmetic Treatments – Opportunity for BTX.....III-40
1$200
   Botulinum Toxin Injections Approved by China Food and Drug Administration
  (CFDA).....III-41
India.....III-41
Table 49: Non-Surgical Aesthetic Procedures in India (2016): Percentage Breakdown of Number of Procedures by Procedure Type (includes corresponding Graph/Chart).....III-41
1$200
   South Korea.....III-42
Botulinum Toxin Market – An Overview.....III-42
Table 50: South Korean Botulinum Toxin Use by Application for the Years 2005, 2010 and 2015 (includes corresponding Graph/Chart).....III-42
1$200
   Strong Demand for Cosmetic Procedures – Potential for BTX Market.....III-43
Table 51: Working Women as % of Total Female Population for 2005, 2010, 2015 & 2016 (includes corresponding Graph/Chart).....III-43
1$200
   Table 52: Aging Population in Korea (2015 & 2025): Percentage Breakdown of Population by Age Group (includes corresponding Graph/Chart).....III-44

Table 53: Foreign Patients Visiting Korea for Plastic Surgery & Dermatology Procedures as a % of Total Visits of Foreign Patients (includes corresponding Graph/Chart).....III-44
1$200
   Meditoxin Dominates Domestic BTX Market.....III-45
Table 54: Leading Players in the South Korean Botulinum Toxin Market (2016): Percentage Breakdown of Sales for Daewoong Pharma, Hugel, Medytox and Others (includes corresponding Graph/Chart).....III-45
1$200
   List of Domestic Botox Products in Korea.....III-461$75
   Strategic Corporate Developments.....III-47
Key Players.....III-47
2$150
   B. Market Analytics.....III-49
Table 55: Asia-Pacific Recent Past, Current & Future Analysis for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Thousand for the Years 2016 through 2024 (includes corresponding Graph/Chart).....III-49
1$200
   Table 56: Asia-Pacific Historic Review for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Thousand for the Years 2011 through 2015 (includes corresponding Graph/Chart).....III-501$200
   Table 57: Asia-Pacific 14-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Dollar Sales for Cosmetic and Therapeutic Markets for the Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-511$200
   A. Market Analysis.....III-52
Current and Future Analysis.....III-52
Latin America: Facial Injectables Market Set for Strong Growth.....III-52
Table 58: Non-Surgical Aesthetic Procedures in Brazil (2016): Percentage Breakdown of Number of Procedures by Procedure Type (includes corresponding Graph/Chart).....III-52
1$200
   Israel: Health Ministry Bans Cosmetic Botox Treatment by Dentists.....III-53
Botox Approvals and Indications in RoW.....III-53
Botox Approvals and Indications in Select Latin American Regions.....III-53
Botox Approvals and Indications in Other Select Global Regions.....III-53
1$75
   B. Market Analytics.....III-54
Table 59: Rest of World Recent Past, Current & Future Analysis for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Thousand for the Years 2016 through 2024 (includes corresponding Graph/Chart).....III-54
1$200
   Table 60: Rest of World Historic Review for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Thousand for the Years 2011 through 2015 (includes corresponding Graph/Chart).....III-551$200
   Table 61: Rest of World 14-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Dollar Sales for Cosmetic and Therapeutic Markets for the Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-561$200
  
Total Companies Profiled: 14 (including Divisions/Subsidiaries - 17)

Region/Country Players

The United States 5 Japan 1 Europe 5 France 1 Germany 1 The United Kingdom 1 Rest of Europe 2 Asia-Pacific (Excluding Japan) 6
Click here to request a full table of contents and more details on this project.